Member Info for sadoldgit

Parrot Talk you could feel the desperation by the amount and content of his posts

Posting last thing at night and first thing in the morning in a vain effort to discourage any buying and promote selling.

Added to his short at sub 75p

Price nudged 87.5.

Clearly not have the funds or had doubts about its own convictions.

It has been awfully quiet so clearly nothing to brag about.

Been here a long time and l reckon the end game is in sight.

As a side note it is interesting to note other diseases associated with Psoriasis and therefore easily understandable as to why Tim and Co chose this route

Use of iomarkers here will reap benefits regards to predicting efficacy in other Indications.

Regards

Psoriasis is associated and can lead to many other auto immune diseases as indicated in the link below.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323693/

Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959504/#:~:text=Blocking%20both%20Tyk2%20and%20Jak1,combination%20of%20Jak1%20and%20Tyk2

Inflammatory bowel disease is a potential big market l feel

Reasonings behind this thinking is that although we are primarily Tyk2 with Jak1 we also contain Jak2 and 3 which we are heavily selective over with Jak1.

Jak1 and 3 has proven successful in Ulcerative Colitus with regards to efficacy.

Unlikely that Allosteric Tyk2 can achieve satisfactory results on the above indicated by Deucravacitinib failure to meet end points in UC.

1801 and 1802 are comprised of 31 patented molecules from memory and although both share this composite make up, there will exist subtle differences that will make l more effective in Immuno therapy and the other more effective in immuno oncology.

If left untreated most cases of IBD lead to cancer of the bowel. There is very little difference between CD and UC.

Without wishing to appear overly optimistic we are heading in the right direction at the right time.

I am sure that if and when good results are obtained and SDC1802 receives clinical trial approval Potnak will be around the millionaire status. Not guaranteed of course but good probability.

Regards to all and have a great weekend.

Although as you have stated before Potnak that you make the same percentage gain as me, l only need it to be around 350 million market cap.

Regards

Good afternoon Damion

I asked the advantages of prexasertib over 737 and vica versa not how much data is out there.

I find you very confusing as in a previous post you effectively state that main aim of Sareum is not Psoriasis and they don't believe they can better Deucravacitinib

I am not aware of any of the above and seriously doubt the reasonings behind such absurd claims.

Regards

Pexasertib is a both a checkpoint 1 and checkpoint kinase 2 inhibitor

CCT245737 is Checkpoint kinase 1 inhibitor.

Are there advantages of prexasertib over SRA737 or are there advantages of 737 over Prexasertib?

Regards

Sareum raising funds to enable completion of Phase 1a /1b clinical trial is definitely a victory.

One thing more there is no guarantee that Sareum will need to draw down the full amount.

I am firmly of the belief that this amount was made available to prove the ability to be able to access funds that will enable clinical dose escalation studies to be approved.

Regards

Good Post C79.

It was stated by Sareum at AGM that the interested parties require data hence the considerable effort put in to development of clinical trial.

Dose escalation data of paramount Importance to an interested pharma.

Regards

Plenty of us here prepared to buy on a drop

There are 2 sides to a coin and whilst most of us can see both sides. There is at least one who recalcitrantly is only prepared to see one side.

At present translational studies are continuing

with 1802.

With regards to development we sit in a great position to carry out these studies.

Allosteric Tyk2 has not shown the efficacy that was hyped up to be.

Clearly it is evident that Tyk 2 on its own an be tailored to have greater efficacy in Indications with the addition of Jaks 1,2 &3

Those of us that have been here a while will know that 100% selectivity of a single Jak cannot be obtained. However, a Jak selectivity can be obtained to give the desired effects in a particular indication or Indications

No such thing here as one size file fits aĺl as demonstrated by deucravacitinib in UC.

The thinking behind the Allosteric Tyk2 is clearly along the same lines as the early Jak1 Jak2 and Jak3 formulated compounds that were given black box warnings by the US regulatory authority.

We are far from alone in believing that we can create a compound with greater efficacy in the indication of Psoriasis than Deucravacitinib.

737 is a complex issue as there are an increasing number of suitable candidates that it can be partnered with thT overcome many of the problems associated with cancer developing resistance to CHK1 inhibition.

What cannot be ruled out is an agreement at so.e time resulting in Combination therapy leading to clinical trial. It could be announced any time but no indication as to when

Regards

Good afternoon.

Many moons ago BRAF was in Sareums planned pipeline along with several other compounds but due to concentration on CCT245737 and later SDC compounds that require funds these are no longer being developed by Sareum

It does Indicate however considerable knowledge in the field of oncology.

Another blue day and looking good for it to continue to do so for a while.

Regards

Good morning Ahfam

It may well be that the tax they can claim back cannot be taken into account with regards to clinical trial funding as any proof of finance

In this aspect it may well be that some of the claimed tax back will reduce the need to draw down money from Riverfort or indeed pay money back.

Food for thought.

Most important of all is the continuing of dose escalation in clinical trial.

Regards

I would hazard a guess as shown trade is above mid price.

Riverfort would have taken the 50k arrangement fee out, that l feel for sure.

They will sell some yes of course.

As far as l see it as for what we have the current Sp is peanuts even in the current market of AIM

and the current pharma sector in particular.

C79 a decent top up lad.

It will all come to fruition l feel in the not too distant future.

One thing did occur to me.

On the original trial application in UK one of the requirements was to prove the sbility to provide funding for the trial.

As far as l can see there is no difference with the trials in OZ.

Have Sareum.played a master stroke here in the current climate?

They can finance to end of 1b as l see it.

You have always been a great steadfast poster of information to this chat board and have never yielded to the naysayers. Some of us have responded but not always reaching the intended result. Good posts are lost in the resulting slanging.

Yes long term.inveztors do get peeved but you have remained head held high and not succumbed to the absolute drivel and vain attempts of the professional sentiment adjusters that set out to promote fear.

Well done and am sure you along with many long term.holders and that includes those that have bought sold on a profit and reinvested will be rewarded

Regards and all the very best to you lad.

Good post Krone. Good to see what else is developing.

Interestingly Beprocitinib Tyk2 Jak1 replaced by Ropsacitinib Tyk2 with around 5x greater selectivity of Jak2 over Jak1.

Tyk 2 on its own whilst good in some Indications will prove non satisfactory in others.

There exists a balance between Tyk2 selectivity and Jakis in certain amounts and certain degrees of selectivity based on Jaks 1 2 and 3 selectivity.

Our SDC 1801 Tyk2 with Jak1 of around 5 x the selectivity over Jaks 2 and 3.

Then ofcourse we also have the importance of purity in a pharmaceutical compound.

One of the major reasons drugs fail in clinical trial is lack of thoroughness in preclinical. Effectively attention to detail.

Purity and attention to detail are applied in abundance by Sareum to their compounds.

Not all Tyk2 compounds or Tyk2 compounds with their associated Jakis the same.

In effect they can be tailor made to treat a particular indication l feel at the same time no su h thing as one Co.pound fits all.

Regards

I reckon there is some individual wandering around the green looking for a set of bent golf clubs.

A healthy day with good buying.

Regards

Both conspicuous by their silence Ahfam.

As l pointed out to one of them

If the price falls I can buy more , if the price goes up l can sell

They by the very nature of a short have o ly one option if they have set what is effectively a stop loss.

To buy at effectively 75p and a rise up to 87p a loss of around 15% maybe more dependant on spread.

So the 12.5% gain one had the option to take is now looking at that well and truly wiped out

They may have maintained a margin if they had absolutely no concerns of the price rising.

Yes very quiet on the death spiral front.

Some normality returned to this chatboard l am glad to say.

Regards

A shareholder is a stakeholder

A stakeholder is not necessarily a shareholder

On reflection I am certain that in any ongoing discussions with the CPF that they themselves would be under an NDA. Sareum therefore will be informed as a stakeholder of any outcome but nothing else.

Regards

HBD

Sareum have a 27.5% financial interest and that is all. They are not a shareholder in anyway.

There would be no requirement for the CPF to notify Sareum of any developments with the exception of any financial agreement between the CPF and the interested party whereby a date and amount of payment to be made normally in the form that was gi en previously as a copy of contract or on licensing agreement.

Should Sareum be a shareholder of CPF then notifications and non disclosure agreements would be in place.

Of this l am 99.9 % certain.

Regards